Testosterone and the cardiovascular system

Wolters Kluwer delivers strong Lippincott journal performance in 2023 Journal Citation Reports

Retrieved on: 
Wednesday, August 9, 2023

Wolters Kluwer Health today announced strong results for the Lippincott portfolio of journals in the 2022 Journal Impact Factor (JIF), the journal metric released annually by Clarivate Analytics as part of the Journal Citation Reports (JCR).

Key Points: 
  • Wolters Kluwer Health today announced strong results for the Lippincott portfolio of journals in the 2022 Journal Impact Factor (JIF), the journal metric released annually by Clarivate Analytics as part of the Journal Citation Reports (JCR).
  • The 2023 rankings featured 387 Wolters Kluwer journals, with more than half (52%) receiving improved rankings from the previous year and an overall net increase for the portfolio.
  • To learn more about the titles within the Wolters Kluwer Lippincott publishing lineup, please visit lww.com .
  • The division of Wolters Kluwer supports clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions.

In Celebration of "Orgasm Day" The Cellular Medicine Association Offers a Free Course, The Female Orgasm System

Retrieved on: 
Thursday, July 27, 2023

Music and food are sometimes called "orgasmic" because orgasm is considered to be the ultimate pleasure; but orgasm is not just about pleasure.

Key Points: 
  • Music and food are sometimes called "orgasmic" because orgasm is considered to be the ultimate pleasure; but orgasm is not just about pleasure.
  • Similarly, the Reproductive System and the Orgasm System share components but are not the same."
  • Dr. Runels, the inventor of the O-Shot® procedure , author of multiple research papers and books, and first to use the terminology "Female Orgasm System," is offering an online seven-week course teaching the Female Orgasm System in hopes of narrowing the orgasm gap.
  • The course is sponsored by the Cellular Medicine Association (CMA) .

Global Deep Venous Disease Treatment Devices Market is Expected to Reach $2.4 Billion by 2032: Rise in Diagnosis of Deep Venous Diseases in Hospitals Leading to Increased Use of Treatment Devices - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 19, 2023

The global deep venous disease treatment devices market is in the developed phase.

Key Points: 
  • The global deep venous disease treatment devices market is in the developed phase.
  • Among the sectors of the healthcare ecosystem that got less impacted by the pandemic are the deep venous disease treatment devices.
  • The global deep venous disease treatment devices market (by end user) is expected to be dominated by the hospitals and clinics segment.
  • The global deep venous disease treatment devices market (by region) is dominated by the North America segment.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ANGN, FOCS, UNVR, CSII

Retrieved on: 
Wednesday, April 12, 2023

It is free and there is no cost or obligation to you.

Key Points: 
  • It is free and there is no cost or obligation to you.
  • Focus Financial Partners Inc. (NASDAQ: FOCS ), relating to its proposed sale to affiliates of Clayton Dubilier & Rice LLC.
  • Under the terms of the agreement, FOCS shareholders are expected to receive $53.00 in cash per share they own.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NUVA, CSII, ANGN, AGFS

Retrieved on: 
Wednesday, April 5, 2023

Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.

Key Points: 
  • Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.
  • Under the terms of the agreement, AGFS shareholders are expected to receive $3.00 in cash per share they own.

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – ANGN, CSII, AGFS, NUVA

Retrieved on: 
Wednesday, March 29, 2023

It is free and there is no cost or obligation to you.

Key Points: 
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.
  • Under the terms of the agreement, AGFS shareholders are expected to receive $3.00 in cash per share they own.
  • Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NUVA, ANGN, AGFS, CSII

Retrieved on: 
Wednesday, March 22, 2023

Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.

Key Points: 
  • Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.
  • Angion Biomedica Corp. (NASDAQ: ANGN ), relating to its proposed merger with Elicio Therapeutics.
  • Under the terms of the agreement, AGFS shareholders are expected to receive $3.00 in cash per share they own.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – AGFS, NUVA, CSII, ANGN

Retrieved on: 
Wednesday, March 15, 2023

Under the terms of the agreement, AGFS shareholders are expected to receive $3.00 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, AGFS shareholders are expected to receive $3.00 in cash per share they own.
  • Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.
  • Under the terms of the agreement, Elicio shareholders are expected to receive new shares of ANGN, with ANGN shareholders expected to own approximately 34.5% of the combined company.

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – TIG, NBTB, CSII, MPB

Retrieved on: 
Wednesday, March 1, 2023

Under the terms of the agreement, TIG shareholders are expected to receive $6.15 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, TIG shareholders are expected to receive $6.15 in cash per share they own.
  • NBT Bancorp Inc. (NASDAQ: NBTB ) relating to its proposed merger with Salisbury Bancorp, Inc.
  • Under the terms of the merger, Salisbury shareholders will receive 0.745 shares of NBT per share they own.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.

ALERT: The M&A Class Action Firm Continues its Investigation of the Merger – NBTB, MPB, CSII, NUVA

Retrieved on: 
Wednesday, February 22, 2023

Under the terms of the merger, Salisbury shareholders will receive 0.745 shares of NBT per share they own.

Key Points: 
  • Under the terms of the merger, Salisbury shareholders will receive 0.745 shares of NBT per share they own.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.
  • Under the terms of the agreement, NUVA shareholders are expected to receive 0.75 shares of Globus per share they own.